Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
Harvard University · Massachusetts General Hospital · +3 more institutions
Abstract
Cancers of origin in the gallbladder and bile ducts are rarely curable with current modalities of cancer treatment. Our clinical application of broad-based mutational profiling for patients diagnosed with a gastrointestinal malignancy has led to the novel discovery of mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) in tumors from a subset of patients with cholangiocarcinoma. A total of 287 tumors from gastrointestinal cancer patients (biliary tract, colorectal, gastroesophageal, liver, pancreatic, and small intestine carcinoma) were tested during routine clinical evaluation for 130 site-specific mutations within 15 cancer genes. Mutations were identified within a number of genes, including…
Citation impact
- FWCI
- 34.97
- Percentile
- 100%
- References
- 47
Authors
18- DRDarrell R. BorgerCorresponding
Harvard University, Massachusetts General Hospital, Center for Cancer Research
- KKKenneth K. Tanabe
Harvard University, Massachusetts General Hospital, Center for Cancer Research
- KCKenneth C. Fan
Massachusetts General Hospital, Center for Cancer Research
- HUHector U. Lopez
Massachusetts General Hospital, Center for Cancer Research
- VRValeria R. Fantin
Agios Pharmaceuticals (United States)
Topics & keywords
- Isocitrate dehydrogenase
- IDH1
- IDH2
- KRAS
- Intrahepatic Cholangiocarcinoma
- Gallbladder
- PTEN
- Bile duct
- Good health and well-being